Status Awaiting development
Decision None selected
Process TA
ID number 3769


Key events during the development of the guidance:

Date Update
23 November 2022 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Naxitamab with GM-CSF within its marketing authorisation for treating relapsed or refractory high-risk neuroblastoma. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available.
01 April 2020 Topic has been referred

For further information on our processes and methods, please see our CHTE processes and methods manual